Medannex Ltd Information

Medannex is pioneering the targeting of annexin-A1 to provide powerful new treatment options for people impacted by cancers and autoimmune diseases. Annexin-A1 drives cancer cell growth and migration and also plays a key role in the development of several autoimmune conditions. Extensive pre-clinical data demonstrate that our first-in-class monoclonal antibody therapeutic (MDX-124) effectively blocks the action of annexin-A1. A Phase 1b clinical study is under way, in cancer patients. In parallel, we are currently preparing for further clinical studies in autoimmune diseases.